GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why
GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.
News Medical on MSN6h
Interactive atlas unveils immune changes in multiple myeloma
Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
Cancer Therapy Advisor10h
Eque-cel Elicits Responses in Heavily Pretreated Multiple Myeloma
Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.
BioSpace11h
GSK Builds Case for Blenrep with Multiple Myeloma OS Data That Bests J&J’s Darzalex
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.
Targeted Oncology2d
Fellow's Perspective: Patient Case of Newly Diagnosed Multiple Myeloma
This looked at patients with transplant-eligible newly diagnosed multiple myeloma ... survival [PFS], as well as overall ...
Pharmabiz3d
Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma
Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...
Hosted on MSN4d
Opinion: Myeloma Explained — Insights Into The Disease And Its Treatment
Multiple Myeloma is a type of blood cancer that develops in plasma ... can provide patients with extended survival and ...